Acorda Therapeutics Reports First Quarter 2013 Financial Results

Published May 2, 2013

Acorda Therapeutics Reports First Quarter 2013 Financial Results

Filed under: drug treatment programs in maryland

Underlying consumer demand also remained strong and we are maintaining our 2013 AMPYRA net sales guidance of $ 285-$ 315 million,” said Ron Cohen, M.D., Acorda Therapeutics' President and CEO. … R&D expenses for the quarter ended March 31, 2013 …
Read more on Business Wire (press release)

Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the …

Filed under: drug treatment programs in maryland

"This study is evidence of Shire's commitment to conducting research in ADHD and contributing to the body of knowledge about treatment options," said Arnaud Partiot, M.D., Ph.D., senior vice president and head of Research and Development for Shire.
Read more on Sacramento Bee

Study Finds Less-Used Regimen For Treating Children In Africa With HIV Is …

Filed under: drug treatment programs in maryland

Senior author Robert Gross, MD, MSCE, an associate professor of Infectious Diseases and Epidemiology at Penn Medicine, adds, “Given this evidence, it is very reasonable to adjust pediatric HIV treatment guidelines. However, as we move towards … “In …
Read more on RedOrbit